Intrinsic value of AVEO Pharmaceuticals - AVEO

Previous Close

$3.03

  Intrinsic Value

$0.06

stock screener

  Rating & Target

str. sell

-98%

  Value-price divergence*

0%

Previous close

$3.03

 
Intrinsic value

$0.06

 
Up/down potential

-98%

 
Rating

str. sell

 
Value-price divergence*

0%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of AVEO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -84.21
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  3
  5
  7
  11
  16
  23
  31
  42
  55
  71
  89
  111
  136
  164
  195
  229
  266
  307
  350
  397
  446
  498
  553
  610
  671
  734
  799
  868
  939
  1,013
  1,090
Variable operating expenses, $m
 
  8
  12
  18
  27
  38
  52
  70
  92
  118
  149
  185
  226
  273
  325
  382
  444
  511
  584
  661
  743
  830
  922
  1,018
  1,118
  1,223
  1,333
  1,446
  1,565
  1,688
  1,817
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  32
  8
  12
  18
  27
  38
  52
  70
  92
  118
  149
  185
  226
  273
  325
  382
  444
  511
  584
  661
  743
  830
  922
  1,018
  1,118
  1,223
  1,333
  1,446
  1,565
  1,688
  1,817
Operating income, $m
  -29
  -3
  -5
  -7
  -11
  -15
  -21
  -28
  -37
  -47
  -60
  -74
  -91
  -109
  -130
  -153
  -178
  -205
  -234
  -265
  -297
  -332
  -369
  -407
  -447
  -489
  -533
  -579
  -626
  -676
  -727
EBITDA, $m
  -29
  -3
  -5
  -7
  -11
  -15
  -21
  -28
  -37
  -47
  -60
  -74
  -91
  -109
  -130
  -153
  -178
  -205
  -234
  -265
  -297
  -332
  -369
  -407
  -447
  -489
  -533
  -579
  -626
  -676
  -727
Interest expense (income), $m
  2
  2
  4
  8
  13
  20
  29
  41
  56
  75
  97
  124
  154
  189
  228
  272
  320
  373
  430
  491
  557
  626
  700
  777
  859
  944
  1,032
  1,125
  1,222
  1,322
  1,426
Earnings before tax, $m
  -27
  -6
  -9
  -15
  -24
  -35
  -50
  -69
  -93
  -122
  -157
  -198
  -245
  -298
  -358
  -425
  -498
  -578
  -664
  -756
  -854
  -959
  -1,069
  -1,185
  -1,306
  -1,433
  -1,566
  -1,704
  -1,848
  -1,997
  -2,153
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -27
  -6
  -9
  -15
  -24
  -35
  -50
  -69
  -93
  -122
  -157
  -198
  -245
  -298
  -358
  -425
  -498
  -578
  -664
  -756
  -854
  -959
  -1,069
  -1,185
  -1,306
  -1,433
  -1,566
  -1,704
  -1,848
  -1,997
  -2,153

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  23
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  27
  43
  67
  100
  145
  205
  281
  377
  496
  638
  805
  1,000
  1,223
  1,474
  1,754
  2,062
  2,399
  2,763
  3,155
  3,573
  4,017
  4,486
  4,981
  5,500
  6,043
  6,610
  7,201
  7,817
  8,458
  9,125
  9,817
Adjusted assets (=assets-cash), $m
  4
  43
  67
  100
  145
  205
  281
  377
  496
  638
  805
  1,000
  1,223
  1,474
  1,754
  2,062
  2,399
  2,763
  3,155
  3,573
  4,017
  4,486
  4,981
  5,500
  6,043
  6,610
  7,201
  7,817
  8,458
  9,125
  9,817
Revenue / Adjusted assets
  0.750
  0.116
  0.104
  0.110
  0.110
  0.112
  0.110
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
  0.111
Average production assets, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Working capital, $m
  16
  0
  -1
  -1
  -2
  -2
  -3
  -4
  -6
  -7
  -9
  -11
  -14
  -16
  -19
  -23
  -27
  -31
  -35
  -40
  -45
  -50
  -55
  -61
  -67
  -73
  -80
  -87
  -94
  -101
  -109
Total debt, $m
  14
  24
  45
  75
  115
  169
  238
  325
  431
  559
  710
  885
  1,086
  1,312
  1,563
  1,841
  2,144
  2,472
  2,824
  3,201
  3,600
  4,023
  4,468
  4,935
  5,423
  5,934
  6,466
  7,021
  7,597
  8,197
  8,820
Total liabilities, $m
  29
  39
  60
  90
  130
  184
  253
  340
  446
  574
  725
  900
  1,101
  1,327
  1,578
  1,856
  2,159
  2,487
  2,839
  3,216
  3,615
  4,038
  4,483
  4,950
  5,438
  5,949
  6,481
  7,036
  7,612
  8,212
  8,835
Total equity, $m
  -2
  4
  7
  10
  14
  20
  28
  38
  50
  64
  81
  100
  122
  147
  175
  206
  240
  276
  315
  357
  402
  449
  498
  550
  604
  661
  720
  782
  846
  912
  982
Total liabilities and equity, $m
  27
  43
  67
  100
  144
  204
  281
  378
  496
  638
  806
  1,000
  1,223
  1,474
  1,753
  2,062
  2,399
  2,763
  3,154
  3,573
  4,017
  4,487
  4,981
  5,500
  6,042
  6,610
  7,201
  7,818
  8,458
  9,124
  9,817
Debt-to-equity ratio
  -7.000
  5.530
  6.750
  7.500
  7.970
  8.270
  8.470
  8.600
  8.700
  8.760
  8.810
  8.850
  8.880
  8.900
  8.910
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.980
  8.980
Adjusted equity ratio
  -6.250
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -27
  -6
  -9
  -15
  -24
  -35
  -50
  -69
  -93
  -122
  -157
  -198
  -245
  -298
  -358
  -425
  -498
  -578
  -664
  -756
  -854
  -959
  -1,069
  -1,185
  -1,306
  -1,433
  -1,566
  -1,704
  -1,848
  -1,997
  -2,153
Depreciation, amort., depletion, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Funds from operations, $m
  -37
  -6
  -9
  -15
  -24
  -35
  -50
  -69
  -93
  -122
  -157
  -198
  -245
  -298
  -358
  -425
  -498
  -578
  -664
  -756
  -854
  -959
  -1,069
  -1,185
  -1,306
  -1,433
  -1,566
  -1,704
  -1,848
  -1,997
  -2,153
Change in working capital, $m
  -6
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -7
  -7
  -8
Cash from operations, $m
  -31
  -5
  -9
  -15
  -23
  -35
  -49
  -68
  -92
  -121
  -155
  -195
  -242
  -295
  -355
  -421
  -494
  -574
  -659
  -751
  -849
  -953
  -1,063
  -1,179
  -1,300
  -1,427
  -1,559
  -1,697
  -1,841
  -1,990
  -2,145
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
New CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from investing activities, $m
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Free cash flow, $m
  -32
  -5
  -9
  -15
  -23
  -35
  -49
  -68
  -92
  -121
  -155
  -195
  -242
  -295
  -355
  -421
  -494
  -574
  -659
  -751
  -849
  -953
  -1,063
  -1,179
  -1,300
  -1,427
  -1,559
  -1,697
  -1,841
  -1,990
  -2,145
Issuance/(repayment) of debt, $m
  5
  10
  21
  30
  41
  54
  69
  87
  106
  128
  151
  175
  200
  226
  252
  278
  303
  328
  352
  376
  400
  423
  445
  467
  489
  511
  532
  554
  577
  600
  623
Issuance/(repurchase) of shares, $m
  15
  12
  11
  19
  28
  41
  58
  79
  105
  136
  174
  217
  267
  323
  386
  456
  532
  614
  703
  798
  899
  1,006
  1,118
  1,236
  1,360
  1,490
  1,625
  1,765
  1,912
  2,064
  2,222
Cash from financing (excl. dividends), $m  
  20
  22
  32
  49
  69
  95
  127
  166
  211
  264
  325
  392
  467
  549
  638
  734
  835
  942
  1,055
  1,174
  1,299
  1,429
  1,563
  1,703
  1,849
  2,001
  2,157
  2,319
  2,489
  2,664
  2,845
Total cash flow (excl. dividends), $m
  -12
  16
  24
  33
  46
  60
  78
  97
  119
  144
  170
  197
  225
  254
  283
  312
  340
  368
  396
  423
  449
  475
  500
  525
  549
  574
  598
  623
  648
  674
  700
Retained Cash Flow (-), $m
  19
  -12
  -11
  -19
  -28
  -41
  -58
  -79
  -105
  -136
  -174
  -217
  -267
  -323
  -386
  -456
  -532
  -614
  -703
  -798
  -899
  -1,006
  -1,118
  -1,236
  -1,360
  -1,490
  -1,625
  -1,765
  -1,912
  -2,064
  -2,222
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  4
  12
  15
  17
  19
  20
  18
  14
  7
  -4
  -20
  -42
  -69
  -103
  -144
  -191
  -246
  -307
  -375
  -450
  -531
  -618
  -712
  -811
  -916
  -1,027
  -1,143
  -1,264
  -1,390
  -1,522
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  4
  11
  13
  14
  15
  14
  12
  9
  4
  -2
  -10
  -18
  -26
  -35
  -42
  -49
  -53
  -57
  -58
  -57
  -55
  -51
  -47
  -41
  -36
  -30
  -25
  -20
  -15
  -11
Current shareholders' claim on cash, %
  100
  50.0
  13.7
  3.6
  0.9
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company’s pipeline of product candidates include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors for renal cell carcinoma and other cancers; Ficlatuzumab, an anti-hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer, including chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

FINANCIAL RATIOS  of  AVEO Pharmaceuticals (AVEO)

Valuation Ratios
P/E Ratio -8.5
Price to Sales 76.6
Price to Book -114.9
Price to Tangible Book
Price to Cash Flow -7.4
Price to Free Cash Flow -7.4
Growth Rates
Sales Growth Rate -84.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate -100%
Financial Strength
Quick Ratio 12
Current Ratio 0.2
LT Debt to Equity -600%
Total Debt to Equity -700%
Interest Coverage -13
Management Effectiveness
Return On Assets -73.5%
Ret/ On Assets - 3 Yr. Avg. -47.9%
Return On Total Capital -142.1%
Ret/ On T. Cap. - 3 Yr. Avg. -89%
Return On Equity -360%
Return On Equity - 3 Yr. Avg. -185.1%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -833.3%
EBITDA Margin - 3 Yr. Avg. -366.4%
Operating Margin -966.7%
Oper. Margin - 3 Yr. Avg. -437.7%
Pre-Tax Margin -900%
Pre-Tax Margin - 3 Yr. Avg. -424.5%
Net Profit Margin -900%
Net Profit Margin - 3 Yr. Avg. -424.5%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

AVEO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AVEO stock intrinsic value calculation we used $3 million for the last fiscal year's total revenue generated by AVEO Pharmaceuticals. The default revenue input number comes from 2016 income statement of AVEO Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AVEO stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for AVEO is calculated based on our internal credit rating of AVEO Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of AVEO Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AVEO stock the variable cost ratio is equal to 166.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for AVEO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 17.4% for AVEO Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for AVEO Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AVEO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AVEO are equal to 0%.

Life of production assets of 10 years is the average useful life of capital assets used in AVEO Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AVEO is equal to -10%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-2 million for AVEO Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 77.633 million for AVEO Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of AVEO Pharmaceuticals at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
NVS Novartis ADR 83.18 35.73  str.sell
ARQL ArQule 1.05 0.10  str.sell
INCY Incyte 121.74 293.88  str.buy
BMY Bristol-Myers 56.77 26.07  str.sell
AMGN Amgen 167.81 182.48  hold
EXEL Exelixis 26.88 53.04  str.buy

COMPANY NEWS

▶ AVEO reports 2Q loss   [Aug-09-17 10:09PM  Associated Press]
▶ LD Micro Index Reconstitution as of August 1, 2017   [Aug-01-17 09:40AM  ACCESSWIRE]
▶ Here's Why AVEO Oncology Rose as Much as 15% Today   [Jul-19-17 02:01PM  Motley Fool]
▶ Here's Why AVEO Oncology Fell as Much as 12.7% Today   [Jul-11-17 04:21PM  Motley Fool]
▶ Company News for July 10, 2017   [Jul-10-17 10:13AM  Zacks]
▶ Here's Why AVEO Oncology Rose As Much As 13.8% Today   [Jun-27-17 04:30PM  Motley Fool]
▶ Biotech Stocks Showing Signs of Resurgence   [Jun-26-17 08:30AM  PR Newswire]
▶ AVEO reports 1Q loss   [May-04-17 08:58AM  Associated Press]
▶ AVEO Announces Milestone Payment from CANbridge for AV-203   [Apr-03-17 07:00AM  Business Wire]
▶ GGP, CenturyLink Drop into Tuesdays 52-Week Low Club   [Mar-28-17 04:04PM  24/7 Wall St.]
▶ AVEO reports 4Q loss   [Mar-22-17 04:22PM  Associated Press]
▶ Aveo Cancer Drug Tivozanib Clears Safety Review   [Feb-24-17 10:23AM  at Investopedia]
▶ 5 Biotech Penny Stocks Smart Money Is Piling On   [Oct-23-16 04:23PM  at Insider Monkey]
▶ AVEO to Present at the 15th Annual BIO Investor Forum   [Oct-12-16 07:00AM  Business Wire]
Stock chart of AVEO Financial statements of AVEO
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.